Active	Status	Sponsor type	Region	Phase	Filter
3 Active 5 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hickish, Tamas
PRIMUS 001, NCT04151277 / ISRCTN75002153 / 2016-004155-67: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer	Recruiting	2	500	Europe	FOLFOX-A, Gemcitabe and Abraxane, G-CSF	Judith Dixon-Hughes, NHS Greater Glasgow and Clyde, University of Glasgow	Neoplasms Pancreatic	12/25	01/26
FAIM, NCT04920708: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression	Recruiting	2	324	Europe	Ipatasertib 300mg, RG7440, Fulvestrant 500g, Faslodex, Palbociclib 75mg-125mg, Ibrance, CDK4/6 Inhibitor, Abemaciclib / Ribociclib / Palbociclib	Royal Marsden NHS Foundation Trust, Pfizer, Hoffmann-La Roche	Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer	09/26	09/26
NCT04161417: Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer	Recruiting	N/A	2500	Europe	Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling	Judith Dixon-Hughes, Cancer Research UK, NHS Greater Glasgow and Clyde	Neoplasms Pancreatic	12/25	12/25